Nugene International Stock Performance
| NUGN Stock | USD 0.01 0.0001 2.00% |
On a scale of 0 to 100, NuGene International holds a performance score of 2. The company secures a Beta (Market Risk) of -0.46, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning NuGene International are expected to decrease at a much lower rate. During the bear market, NuGene International is likely to outperform the market. Please check NuGene International's total risk alpha and the relationship between the potential upside and day typical price , to make a quick decision on whether NuGene International's current price movements will revert.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in NuGene International are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, NuGene International displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
NuGene |
NuGene International Relative Risk vs. Return Landscape
If you would invest 0.90 in NuGene International on October 10, 2024 and sell it today you would lose (0.39) from holding NuGene International or give up 43.33% of portfolio value over 90 days. NuGene International is currently generating 0.6027% in daily expected returns and assumes 17.4372% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than NuGene, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
NuGene International Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NuGene International's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as NuGene International, and traders can use it to determine the average amount a NuGene International's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0346
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NUGN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 17.44 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.6 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average NuGene International is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NuGene International by adding it to a well-diversified portfolio.
NuGene International Fundamentals Growth
NuGene Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of NuGene International, and NuGene International fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NuGene Pink Sheet performance.
| Return On Asset | -9.44 | |||
| Profit Margin | (0.11) % | |||
| Operating Margin | (0.11) % | |||
| Current Valuation | 14.83 M | |||
| Shares Outstanding | 219 M | |||
| Price To Earning | (0.03) X | |||
| Price To Sales | 9.65 X | |||
| Revenue | 1.47 M | |||
| EBITDA | (9.03 M) | |||
| Cash And Equivalents | 118.34 K | |||
| Total Debt | 2.8 M | |||
| Debt To Equity | 1.05 % | |||
| Book Value Per Share | 0.10 X | |||
| Cash Flow From Operations | (2 M) | |||
| Earnings Per Share | (0.29) X | |||
| Total Asset | 585 K | |||
| Retained Earnings | (15.32 M) | |||
| Current Asset | 389 K | |||
| Current Liabilities | 4.58 M | |||
About NuGene International Performance
By examining NuGene International's fundamental ratios, stakeholders can obtain critical insights into NuGene International's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that NuGene International is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Livento Group, Inc. engages in the film and television production activities. Livento Group, Inc. was incorporated in 2013 and is based in New York, New York. Nugene International operates under Shell Companies classification in the United States and is traded on OTC Exchange. It employs 11 people.Things to note about NuGene International performance evaluation
Checking the ongoing alerts about NuGene International for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for NuGene International help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NuGene International is way too risky over 90 days horizon | |
| NuGene International has some characteristics of a very speculative penny stock | |
| NuGene International appears to be risky and price may revert if volatility continues | |
| NuGene International has a very high chance of going through financial distress in the upcoming years | |
| NuGene International currently holds 2.8 M in liabilities with Debt to Equity (D/E) ratio of 1.05, which is about average as compared to similar companies. NuGene International has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist NuGene International until it has trouble settling it off, either with new capital or with free cash flow. So, NuGene International's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like NuGene International sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NuGene to invest in growth at high rates of return. When we think about NuGene International's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 1.47 M. Net Loss for the year was (75.19 K) with loss before overhead, payroll, taxes, and interest of (209.4 K). | |
| NuGene International currently holds about 118.34 K in cash with (2 M) of positive cash flow from operations. |
- Analyzing NuGene International's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NuGene International's stock is overvalued or undervalued compared to its peers.
- Examining NuGene International's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NuGene International's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NuGene International's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NuGene International's pink sheet. These opinions can provide insight into NuGene International's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in NuGene Pink Sheet
NuGene International financial ratios help investors to determine whether NuGene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NuGene with respect to the benefits of owning NuGene International security.